Mackenzie Financial’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.93M Buy
+102,804
New +$4.42M ﹤0.01% 828
2025
Q4
Sell
-289,551
Closed -$16.1M 1775
2025
Q3
$16.1M Buy
+289,551
New +$16.9M 0.02% 414
2020
Q1
Sell
-20,600
Closed -$596K 1143
2019
Q4
$596K Buy
20,600
+2,800
+16% +$77.5K ﹤0.01% 829
2019
Q3
$460K Buy
17,800
+4,200
+31% +$106K ﹤0.01% 837
2019
Q2
$347K Buy
+13,600
New +$336K ﹤0.01% 930
2018
Q4
Sell
-69,986
Closed -$1.65M 1207
2018
Q3
$1.65M Sell
69,986
-584
-0.8% -$14.3K ﹤0.01% 679
2018
Q2
$1.63M Buy
70,570
+5,780
+9% +$137K ﹤0.01% 620
2018
Q1
$1.59M Buy
64,790
+17,662
+37% +$464K ﹤0.01% 594
2017
Q4
$1.26M Buy
47,128
+9,284
+25% +$236K ﹤0.01% 581
2017
Q3
$911K Sell
37,844
-41,458
-52% -$937K ﹤0.01% 455
2017
Q2
$1.7M Sell
79,302
-15,568
-16% -$314K 0.01% 398
2017
Q1
$1.63M Buy
94,870
+43,178
+84% +$752K 0.01% 417
2016
Q4
$927K Buy
+51,692
New +$937K 0.01% 450

Other funds holding NVO

Mackenzie Financial's NVO Position: Q2 2026 in Review

Mackenzie Financial opened a new position in Novo Nordisk (NVO) in Q2 2026: 102,804 shares worth $4.93M. The stake represents ﹤0.01% of the portfolio and ranks #828 among its holdings. This is a return to the name: Mackenzie Financial previously reported a position in NVO as recently as Q3 2025.

Mackenzie Financial first reported a position in NVO in Q4 2016 and has held it in 13 quarters since. The position peaked at $16.1M in Q3 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Mackenzie Financial held 102,804 shares of Novo Nordisk worth $4.93M as of Q2 2026.
  • Novo Nordisk was a new Mackenzie Financial position in Q2 2026.
  • Novo Nordisk made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #828 holding.
  • Mackenzie Financial first reported a position in Novo Nordisk in Q4 2016 and has held it in 13 quarters since.
  • Mackenzie Financial's Novo Nordisk position peaked at $16.1M in Q3 2025.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.